Wellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge, UK; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, UK.
Wellcome Trust-MRC Cambridge Stem Cell Institute, Cambridge, UK; Department of Haematology, University of Cambridge, Cambridge, UK; Cambridge Institute for Medical Research, Cambridge Biomedical Campus, Hills Road, Cambridge CB2 0XY, UK.
Cancer Cell. 2018 Oct 8;34(4):533-535. doi: 10.1016/j.ccell.2018.09.004.
In this issue of Cancer Cell, de Boer et al. refine a set of acute myeloid leukemia (AML)-enriched plasma membrane markers that can be used to identify, prospectively isolate, and longitudinally track leukemic subclones within individual AML patients, correlating immunophenotypic profiles with specific mutational signatures, transcription, functional behavior, and therapeutic outcomes.
在本期《癌细胞》中，de Boer 等人对一组急性髓系白血病（AML）富集的质膜标记物进行了优化，这些标记物可用于在个体 AML 患者中识别、前瞻性分离和纵向追踪白血病亚克隆，将免疫表型特征与特定的突变特征、转录、功能行为和治疗结果相关联。
